| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/17/2001 | EP1068221A2 Template associated npy y2-receptor agonists |
| 01/17/2001 | EP1068218A2 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 01/17/2001 | EP1068212A1 THIAZOLO 4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| 01/17/2001 | EP1068208A1 Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them |
| 01/17/2001 | EP1068207A1 AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
| 01/17/2001 | EP1068206A1 Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
| 01/17/2001 | EP1068205A1 Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands |
| 01/17/2001 | EP1068202A1 1-(3-heteroarylpropyl- or -prop-2-enyl)-4-benzylpiperidines used as nmda receptor antagonists |
| 01/17/2001 | EP1068199A2 N-aryloxyethyl-indoly-alkylamines for the treatment of depression |
| 01/17/2001 | EP1068198A1 5-heteroaryl substituted indoles |
| 01/17/2001 | EP1068195A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1068193A1 Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d 4? receptor antagonists |
| 01/17/2001 | EP1068186A2 Pharmaceutical compositions and methods for use |
| 01/17/2001 | EP1068185A1 Compounds with activity on muscarinic receptors |
| 01/17/2001 | EP1068184A1 N-aryloxyethylamine derivatives for the treatment of depression |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1067935A1 Acylbenzoxazines for enhancing synaptic response(s) |
| 01/17/2001 | EP1067931A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067918A1 Stable dosage forms of fluoxetine and its enantiomers |
| 01/17/2001 | EP1067917A2 Method of treating dopaminergic and gaba-nergic disorders |
| 01/17/2001 | EP1067906A1 Maximizing effectiveness of substances used to improve health and well being |
| 01/17/2001 | EP1067905A1 Fizzy formulations |
| 01/17/2001 | EP1067904A1 Solid, quick dissolving cetirizine formulations |
| 01/17/2001 | EP0983258A4 N-hydroxy 4-sulfonyl butanamide compounds |
| 01/17/2001 | EP0808325B1 Androstane and pregnane series for allosteric modulation of gaba receptor |
| 01/17/2001 | CN1280578A Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 01/17/2001 | CN1280568A Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 01/17/2001 | CN1280559A A noval phosphate salt of isopropyl-methyl-[-2-(3-n-propoxyphenoxy)ethyl] amine |
| 01/17/2001 | CN1280505A Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant of anti-anxiety drug |
| 01/17/2001 | CN1280499A Use of ginkgo biloba extracts for preparing a medicine |
| 01/17/2001 | CN1280136A Gene sequence and amino-acid sequence of varient omega-conch toxin polypeptide and their preparing method and medicinal use |
| 01/17/2001 | CN1280126A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/17/2001 | CN1280125A Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation |
| 01/17/2001 | CN1280006A Medicine ointment prepared with kapur and other Chinese herbal medicine |
| 01/17/2001 | CN1280004A Preparing method of medicine for curing epilepsy |
| 01/17/2001 | CN1279992A Medicine for curing and preventing upper respiratory infection and its preparing method |
| 01/17/2001 | CN1279986A Compound toad skin preparation for curing epilepsy |
| 01/17/2001 | CN1279980A Health-care medicine for sobering up and eliminating alcoholism |
| 01/17/2001 | CN1279971A Capsule for curing hydrocephalus and its producing method |
| 01/17/2001 | CN1279968A Chinese medicine for curing epilepsy and its producing method |
| 01/17/2001 | CN1279957A Use of puffer liver oil in preparing food for curing poisonous drug dependence |
| 01/17/2001 | CN1279950A Sigma-receptor acting medicine with triterpene compound structure |
| 01/17/2001 | CN1060776C Procell for manufactare of imidazo benzodiazepine derivatives |
| 01/17/2001 | CN1060775C Fused troane-derivatives as neurotransmitter reuptake inhibitors |
| 01/17/2001 | CN1060773C Naphthamide derivatives of 3-beta-amino azabicyclo octane or nonane as heuroleptic agents |
| 01/17/2001 | CN1060772C New Indole, Indazole and benzisoxazole compounds, their process of preparation and pharmaceutical compositions which contain them |
| 01/17/2001 | CN1060768C Pyrazoles and pyrazolopyrimidines |
| 01/17/2001 | CN1060761C New aryl (alkyl) propylamides, process for preparing them and pharmaceutical compositions containing them |
| 01/17/2001 | CN1060676C 治疗癫痫的药物 Drug treatment of epilepsy |
| 01/17/2001 | CN1060675C Medicine for treating epilepsy |
| 01/17/2001 | CN1060666C Chinese medicine paste for abstinence of drug and its preparing method |
| 01/17/2001 | CN1060646C Injection solution for giving up addiction of drug addict and its preparing method |
| 01/16/2001 | US6175013 1-(2-methoxybenzyl)-2-((4-phenyl-1-piperazinyl)methyl)-4-(1h -indol-3-ylmethyl)-2-imidazoline, for example; adminstering to treat anxiety, depression, psychosis, and schizophrenia |
| 01/16/2001 | US6174994 7TM receptor (H2CAA71) |
| 01/16/2001 | US6174993 Short peptides which selectively modulate the activity of serine/threonine kinases |
| 01/16/2001 | US6174924 Treating nerve cell death comprising administering to a subject exhibiting symptoms of nerve cell death or susceptible to nerve cell death a substituted guanidine compound |
| 01/16/2001 | US6174909 For treating analgesia, psychosis, convulsions, epilepsy, anxiety, muscular and movement disorders, spastic disorders or symptoms of huntington's or parkinsons disease |
| 01/16/2001 | US6174895 1-aryl-3-arylmethyl-1,8-naphthyridin-4(1H)-ones |
| 01/16/2001 | US6174890 A synergistic biological, neurometabolic and celltrophic composition comprising antioxidative and -catabolic stress (methionine),-anabolic drugs, vasodilative and normo-lipidemic drugs (nicotinic acid), energoactive and antitoxic |
| 01/16/2001 | US6174883 3-substituted-2-oxindoles derivatives |
| 01/16/2001 | US6174882 Treating psychosis, acute mania, schizophrenia, excessive agression, substance abuse and fungal dermatitis; bipolar, autistism, tic, functional bowel and attention deficit hyperactivity disorders, anxiolytic agents; antidepressants |
| 01/16/2001 | US6174881 Hydroxymethylimidazodiazepines and their esters |
| 01/16/2001 | US6174869 Method for enhancing neurone survival and agents useful for same |
| 01/16/2001 | US6174862 Neuroprotectant administered to patients suffering from alzheimer's disease, human immunodeficiency virus |
| 01/16/2001 | CA2314008A1 2-benzimidazolylamine compounds as orl1-receptor agonists |
| 01/16/2001 | CA2204355C Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 01/16/2001 | CA2018818C Treatment of postmenopausal disorders |
| 01/11/2001 | WO2001002855A1 Prevention and treatment of amyloid-associated disorders |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002567A1 16405 receptor, a g-protein coupled receptor |
| 01/11/2001 | WO2001002561A2 Mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | WO2001002557A1 Neurotrophic factor receptor |
| 01/11/2001 | WO2001002552A2 Double transgenic animals as models for neurodegenerative disease |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002549A2 Homomeric and heteromeric ampa receptors |
| 01/11/2001 | WO2001002409A1 Thieno- and furopyrimidine derivatives as a2a-receptor antagonists |
| 01/11/2001 | WO2001002406A1 Potassium channel blocking agents |
| 01/11/2001 | WO2001002405A1 Quinuclidine derivatives for treatment of neurological disorders |
| 01/11/2001 | WO2001002393A1 Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| 01/11/2001 | WO2001002392A1 Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| 01/11/2001 | WO2001002388A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | WO2001002387A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002380A1 Antipsychotic cyclic n-aralkyl amines |
| 01/11/2001 | WO2001002379A1 Selective npy (y5) antagonists |
| 01/11/2001 | WO2001002376A1 Amino-alkyl derivatives |
| 01/11/2001 | WO2001002372A1 Cyclized amino acid derivatives |
| 01/11/2001 | WO2001002368A1 N-heterocyclic derivatives with neuronal activity |
| 01/11/2001 | WO2001002366A2 Substituted isoquinoline derivatives and their use as inticonvulsants |
| 01/11/2001 | WO2001002363A2 N-substituted glycine derivatives |
| 01/11/2001 | WO2001002362A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002361A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002358A2 Cyclized amide derivatives for treating or preventing neuronal damage |
| 01/11/2001 | WO2001002349A1 Phenyl sulfamate derivatives |
| 01/11/2001 | WO2001002342A1 2-aminoindane analogs |
| 01/11/2001 | WO2001001989A1 Novel pharmaceutical combination with analgesic action containing paracetamol and buspirone |
| 01/11/2001 | WO2001001986A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | WO2001001984A1 Levodopa / carbidopa / entacapone pharmaceutical preparation |
| 01/11/2001 | WO2001001983A1 A synergistic combination: gabapentin and pregabalin |
| 01/11/2001 | WO2001001979A1 Therapeutic agents |